

# Human CXCL4L1 Protein

Cat. No. CXC-HM2L1



## Description

<b>Source</b>	Recombinant Human CXCL4L1 Protein is expressed from Expi293 with hFc tag at the C-terminal. It contains Phe31-Ser104.
<b>Accession</b>	P10720
<b>Molecular Weight</b>	The protein has a predicted MW of 35.01 kDa. Due to glycosylation, the protein migrates to 43-48 kDa based on Tris-Bis PAGE result.
<b>Endotoxin</b>	Less than 1EU per µg by the LAL method.
<b>Purity</b>	> 95% as determined by Tris-Bis PAGE > 95% as determined by HPLC

## Formulation and Storage


<b>Formulation</b>	Lyophilized from 0.22µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
<b>Reconstitution</b>	Centrifuge tubes before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.
<b>Storage</b>	-20 to -80°C for 12 months as supplied from date of receipt. -20 to -80°C for 3-6 months in unopened state after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please avoid freeze-thaw cycles.

## Background

Platelet factor-4 (CXCL4/PF-4) was the first chemokine shown to inhibit angiogenesis. CXCL4L1/PF-4var, recently isolated from thrombin-stimulated platelets, differing from authentic CXCL4/PF-4 in three carboxy-terminally located amino acids, was found to be more potent than CXCL4/PF-4 in inhibiting angiogenesis and tumor growth. Both glycosaminoglycans (GAG) and CXCR3 are implicated in the activities of the PF-4 variants.


## Assay Data

### Tris-Bis PAGE



Human CXCL4L1 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.

### SEC-HPLC



The purity of Human CXCL4L1 is greater than 95% as determined by SEC-HPLC.